The University of Chicago Header Logo

Connection

Michael Becker to Treatment Outcome

This is a "connection" page, showing publications Michael Becker has written about Treatment Outcome.
Connection Strength

0.517
  1. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
    View in: PubMed
    Score: 0.051
  2. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.043
  3. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
    View in: PubMed
    Score: 0.040
  4. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
    View in: PubMed
    Score: 0.036
  5. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun; 36(6):1273-82.
    View in: PubMed
    Score: 0.033
  6. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):585-91.
    View in: PubMed
    Score: 0.032
  7. Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transplant. 2008 Jul; 27(7):746-52.
    View in: PubMed
    Score: 0.032
  8. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
    View in: PubMed
    Score: 0.025
  9. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
    View in: PubMed
    Score: 0.021
  10. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
    View in: PubMed
    Score: 0.017
  11. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
    View in: PubMed
    Score: 0.016
  12. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
    View in: PubMed
    Score: 0.014
  13. Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):372-378.
    View in: PubMed
    Score: 0.014
  14. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
    View in: PubMed
    Score: 0.012
  15. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
    View in: PubMed
    Score: 0.012
  16. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.011
  17. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
    View in: PubMed
    Score: 0.010
  18. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
    View in: PubMed
    Score: 0.010
  19. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
    View in: PubMed
    Score: 0.010
  20. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
    View in: PubMed
    Score: 0.010
  21. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
    View in: PubMed
    Score: 0.010
  22. Registration of coronary venous anatomy to the site of the latest mechanical contraction. Acta Cardiol. 2010 Apr; 65(2):161-70.
    View in: PubMed
    Score: 0.009
  23. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
    View in: PubMed
    Score: 0.008
  24. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
    View in: PubMed
    Score: 0.008
  25. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
    View in: PubMed
    Score: 0.008
  26. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91.
    View in: PubMed
    Score: 0.008
  27. Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol. 2004 Oct; 24(10):626-30.
    View in: PubMed
    Score: 0.006
  28. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.006
  29. Comparison of two methods of surfactant administration and the effect on dosing-associated hypoxemia. J Perinatol. 1997 Nov-Dec; 17(6):450-4.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.